News

Findings from an analysis of the REACH2 study, presented at the 2024 Transplantation & Cellular Therapy Meetings, showed that concomitant treatment with azoles does not impact the safety and efficacy of ruxolitinib for patients with acute graft-vs-host-disease.

Betty K. Hamilton, MD, discusses findings from a study comparing gilteritinib vs placebo post-allogeneic hematopoietic cell transplantation for the treatment of patients with FLT3-ITD-positive acute myeloid leukemia.

In early lines of therapy for relapsed/refractory multiple myeloma, patients receiving cilta-cel demonstrated deep and enduring responses, with overall response rates of 95% and 100% in 2 cohorts.

A retrospective study of insurance claims showed patients received ruxolitinib mainly in the second or third line for chronic graft-vs-host disease, with dose adjustment used and no difference shown in time to discontinuation between adult and pediatric patients.

Ruxolitinib cream resulted in positive safety and efficacy findings among a small cohort of patients with cutaneous graft-vs-host disease vs placebo.

An orphan drug designation has been granted by the FDA for IO-202 as a treatment option for patients with chronic myelomonocytic leukemia.

The ruxolitinib and belumosudil combination demonstrated a 55% overall response rate in GVHD, suggesting synergy between inflammatory pathways. The combination was well-tolerated, delayed the need for other therapies.

Michael Scordo, MD, discusses the implications of a new approach to dosing antithymocyte globulin in patients undergoing an allogeneic hematopoietic stem cell transplant.

Acalabrutinib added to axicabtagene ciloleucel treatment was well-tolerated in patients with relapsed/refractory B-cell lymphoma.

Matthew Matasar, MD, highlights the use of mosunetuzumab-axgb for the treatment of patients with follicular lymphoma.

Findings from the phase 3b OReO study showed that patients with ovarian cancer who previously received a PARP inhibitor benefitted from a rechallenge with olaparib.

Ibrahim N. Muhsen, MD, discusses the findings and key takeaways from his presentation given at the 2024 Tandem Meeting.

Findings suggest that liso-cel may be an effective treatment option for patients with relapsed/refractory mantle cell lymphoma and high-risk features, who have limited treatment options.

Linvoseltamab shows promise for patients with heavily pretreated multiple myeloma, achieving a 71% overall response rate in a phase 1/2 trial.

A retrospective study demonstrated the feasibility and efficacy of brexucabtagene autoleucel in treating central nervous system involvement in adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia.

Matthew Matasar, MD, discusses the phase 3 SYMPATICO study of ibrutinib given in combination with venetoclax vs ibrutinib and placebo for the treatment of patients with relapsed/refractory mantle cell lymphoma.

Bruno R. Bastos, MD, discusses the future following a study assessing the changes among patients with renal cell carcinoma who were treated with nivolumab and TPST-1120.

Following a favorable independent data monitoring committee review, the phase 3 PRESERVE 2 trial of trilaciclib in the first-line for patients with metastatic triple negative breast cancer treatment will move forward.

Devices like smart blood pressure cuffs, scales, and even smartphones with health sensors are turning our daily routines into personalized health insights.

IMM-1-104 has gained a fast track designation from the FDA for the treatment of patients with pancreatic ductal adenocarcinoma who have progressed after 1 line of treatment.

The reduced dosing frequency of 1.5 mg/kg every 2 weeks for teclistamab in relapsed/refractory multiple myeloma who have sustained a complete response or better for at least 6 months provides flexibility in dosing schedules for patients.

In an interview with Targeted Oncology, Andreana N. Holowatyj, PhD, MSCI, discussed data from a study which found racial and ethnic differences in susceptibility genes for early-onset colorectal cancer, suggesting current multigene panel tests may not be accurate for diverse populations.

Habte Yimer, MD, provides an overview of the ALPINE trial of zanubrutinib vs ibrutinib among patients with relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.

Adagrasib plus cetuximab as a potential treatment option addresses an unmet need in pretreated KRAS G12C-mutated colorectal cancer, offering hope for improved outcomes.

Ongoing and future trials will attempt to demonstrate the benefi t of NK cell therapies in lymphomas, multiple myeloma, sarcomas, and glioblastoma multiforme, among others.

Pembrolizumab shows promise in advanced endometrial cancer, cutting progression risk by up to 70%. The FDA has granted a priority review for this treatment option.

The FDA has accepted and granted priority review for the new drug application for vorasidenib for the treatment of IDH-mutant diffuse glioma, with a PDUFA action date set for August 20, 2024.

AI is seemingly everywhere, and while its applications in cancer care have increased, it still faces challenges.

Lori J. Wirth, MD, provides an overview on the latest advancements in diagnosis of thyroid cancer.

Stem cell treatments offer hope for a variety of conditions. However, access to these potentially life-altering procedures is often hampered by social factors such as socioeconomic status, race, cultural background, and geographic location.